Hims & Hers Health Reports 38% Revenue Growth to $753.2 Million in Q2 2026

Hims & Hers Health, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company generated total revenue of $753.2 million, marking a 38% increase from $544.8 million in the same quarter of the previous year. For the first half of 2026, revenue reached $1.36 billion, up 20% from $1.13 billion in the first half of 2025. The growth was primarily driven by a surge in the company's Hers brand, particularly in weight loss offerings, and a substantial increase in international revenue following recent acquisitions.

The company's cost of revenue also saw a significant rise, increasing by 112% to $272.4 million for the second quarter, compared to $128.6 million a year earlier. This increase was attributed to higher product and packaging costs, shipping expenses, and costs associated with medical consultation services. Consequently, gross profit for the quarter was $480.8 million, a 16% increase from $416.2 million, resulting in a gross margin of 64%, down from 76% in the prior year. The decline in gross margin was influenced by the higher costs associated with the weight loss offerings and the impact of recent acquisitions.

In terms of operational metrics, Hims & Hers reported a 19% increase in subscribers, reaching approximately 2.9 million by the end of the quarter. Monthly revenue per average subscriber also rose to $92, up from $76 a year prior. The company attributed this growth to enhanced marketing efforts, including a specialized Super Bowl campaign, and improved customer onboarding experiences. The Rest of the World revenue skyrocketed by 1,641% to $131.4 million, largely due to the acquisition of Eucalyptus, which expanded the company's international footprint.

Strategically, Hims & Hers has made several acquisitions to bolster its market position, including the purchase of Eucalyptus for $968.5 million, which is expected to enhance its operations in Australia and other international markets. The company also completed the merger with YourBio, a firm specializing in blood sampling technology, for $153 million. These acquisitions are part of Hims & Hers' broader strategy to diversify its offerings and expand its global reach.

Looking ahead, Hims & Hers anticipates continued growth driven by its investments in marketing, product development, and operational capabilities. However, the company also faces challenges, including rising costs and the need to maintain customer acquisition and retention in a competitive market. The management remains optimistic about leveraging its recent acquisitions and expanding its product offerings to sustain revenue growth in the coming quarters.